急性冠脉综合征患者中基因确诊家族性高胆固醇血症的研究
该研究对103例年龄≤65岁且LDL-C≥160 mg/dl的急性冠脉综合征患者进行FH相关7基因及12个多基因高胆固醇血症常见等位基因检测,基因确诊FH患病率为8.7%,而荷兰脂质临床标准和Simon Broome标准分别漏诊44%和33%的基因确诊患者,提示临床标准分类不准确,应提倡对年轻ACS伴高LDL-C患者进行基因检测。
要点
- 年轻ACS且LDL-C≥160 mg/dl患者中基因确诊FH患病率约9%。
- FH临床标准(DLC和SB)漏诊部分基因确诊FH患者。
- 建议对此类患者行基因检测以识别FH患者及高危亲属。
核心结论
- 在年龄≤65岁且LDL-C≥160 mg/dl的ACS患者中,基因确诊FH患病率较高(约9%)。
- FH临床算法不能准确分类FH患者,DLC和SB标准分别漏诊44%和33%的基因确诊FH患者。
- 应提倡对年轻ACS伴高LDL-C患者进行基因检测,以及时识别FH患者及高危亲属。
研究设计与样本
- 研究对103例年龄≤65岁且LDL-C≥160 mg/dl的ACS患者进行FH相关7基因(LDLR、APOB、PCSK9、APOE、STAP1、LDLRAP1和LIPA)及12个多基因高胆固醇血症常见等位基因的遗传学检测。
- 同时应用荷兰脂质临床(DLC)和Simon Broome(SB)FH临床标准进行评估。
主要发现
- 基因确诊FH的患病率为8.7%(95%CI:4.3%至16.4%;n=9)。
- 无FH变异的患者中,29%(95%CI:18.5%至42.1%;n=18)具有高度提示多基因高胆固醇血症的评分。
- 根据DLC标准,可能至明确FH的患病率为27.2%(95%CI:19.1%至37.0%;n=28);SB标准识别可能至明确FH的患者比例为27.2%(95%CI:19.1%至37.0%;n=28)。
- DLC和SB算法分别未能诊断4例(44%)和3例(33%)基因确诊FH患者。
- 对一级亲属进行级联基因检测额外发现6例FH个体。
关键数值与推荐
- 基因确诊FH患病率:8.7%(95%CI:4.3%至16.4%;n=9)。
- DLC标准可能至明确FH患病率:27.2%(95%CI:19.1%至37.0%;n=28)。
- SB标准可能至明确FH患病率:27.2%(95%CI:19.1%至37.0%;n=28)。
- DLC和SB标准漏诊基因确诊FH比例分别为44%(4例)和33%(3例)。
临床怎么用
- 对年龄≤65岁且LDL-C≥160 mg/dl的ACS患者,应考虑进行FH基因检测以识别基因确诊FH。
- 不应仅依赖DLC或SB临床标准排除FH,因其可能漏诊部分基因确诊患者。
- 基因确诊FH后应进行一级亲属级联基因检测以发现高危个体。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Genetic screening programs in unselected individuals with increased levels of low-density lipoprotein cholesterol (LDL-C) have shown modest results in identifying individuals with familial hypercholesterolemia (FH). OBJECTIVES: This study assessed the prevalence of genetically confirmed FH in patients with acute coronary syndrome (ACS) and compared the diagnostic performance of FH clinical criteria versus FH genetic testing. METHODS: Genetic study of 7 genes (LDLR, APOB, PCSK9, APOE, STAP1, LDLRAP1, and LIPA) associated with FH and 12 common alleles associated with polygenic hypercholesterolemia was performed in 103 patients with ACS, age ≤65 years, and LDL-C levels ≥160 mg/dl. Dutch Lipid Clinic (DLC) and Simon Broome (SB) FH clinical criteria were also applied. RESULTS: The prevalence of genetically confirmed FH was 8.7% (95% confidence interval [CI]: 4.3% to 16.4%; n = 9); 29% (95% CI: 18.5% to 42.1%; n = 18) of patients without FH variants had a score highly suggestive of polygenic hypercholesterolemia. The prevalence of probable to definite FH according to DLC criteria was 27.2% (95% CI: 19.1% to 37.0%; n = 28), whereas SB criteria identified 27.2% of patients (95% CI: 19.1% to 37.0%; n = 28) with possible to definite FH. DLC and SB algorithms failed to diagnose 4 (44%) and 3 (33%) patients with genetically confirmed FH, respectively. Cascade genetic testing in first-degree relatives identified 6 additional individuals with FH. CONCLUSIONS: The prevalence of genetically confirmed FH in patients with ACS age ≤65 years and with LDL-C levels ≥160 mg/dl is high (approximately 9%). FH clinical algorithms do not accurately classify patients with FH. Genetic testing should be advocated in young patients with ACS and high LDL-C levels to allow prompt identification of patients with FH and relatives at risk.
引用
- Amor-Salamanca A, Castillo S, Gonzalez-Vioque E, et al. Genetically Confirmed Familial Hypercholesterolemia in Patients With Acute Coronary Syndrome. J Am Coll Cardiol. 2017. PMID: 28958330. doi:10.1016/j.jacc.2017.08.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。